0001178913-24-001261.txt : 20240408 0001178913-24-001261.hdr.sgml : 20240408 20240408163017 ACCESSION NUMBER: 0001178913-24-001261 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAINREFORM LTD. CENTRAL INDEX KEY: 0001801834 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39481 FILM NUMBER: 24829966 BUSINESS ADDRESS: STREET 1: 65 YIGAL ALON ST. CITY: TEL AVIV STATE: L3 ZIP: 6744316 BUSINESS PHONE: 972-3-7177051 MAIL ADDRESS: STREET 1: 65 YIGAL ALON ST. CITY: TEL AVIV STATE: L3 ZIP: 6744316 6-K 1 zk2431263.htm 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
Report of Foreign Private Issuer
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month of April 2024
 
Commission File Number: 001-39481
 
PainReform Ltd.
(Translation of registrant’s name into English)
 
65 Yigal Alon St., Tel Aviv 6744316
Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F ☒      Form 40-F ☐ 

This Report on Form 6-K is incorporated by reference into the Company’s Registration Statement on Form S-8 (Registration No. 333-257968 and 333-265902) and Form F-3 (Registration No. 333-259318, 333-254982 and 333-276485)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.


On April 8, 2024, an Extraordinary General Meeting of Shareholders of PainReform Ltd. (the “Company”) approved each of the two proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company’s Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders, dated March 7, 2024, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on March 7, 2024.


SIGNATURES 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: April 8, 2024
PAINREFORM LTD.
 
 
 
By:
/s/ Ilan Hadar
 
 
Ilan Hadar
 
 
Chief Executive Officer